Pressure is building on Capitol Hill for Congress to codify President Trump’s “most favored nation” drug-pricing initiative into law.
The administration has already struck deals with more than a dozen drugmakers to sell medicines to Medicaid, the federal-state health plan for low-income individuals and the disabled, at the lowest prices paid by other developed nations. Now lawmakers are debating whether to impose the same framework across the U.S. market.